This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
by Ekta Bagri
BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
Viking Therapeutics to Report Q4 Earnings: Here's What to Know
by Zacks Equity Research
VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.
NVONegative Net Change MRNANegative Net Change VKTXPositive Net Change CSTLPositive Net Change
biotechs
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
by Kanishka Das
CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechs
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
by Zacks Equity Research
Halozyme Therapeutics' shares jump nearly 4% after preliminary 2025 results beat expectations and management lifts 2026 outlook.
RHHBYPositive Net Change JNJPositive Net Change ALKSPositive Net Change HALOPositive Net Change
biotechs
RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER
by Zacks Equity Research
Roche's key drugs lift sales by 7% at CER despite FX headwinds. The company expects mid-single digit sales growth in 2026.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status
by Zacks Equity Research
BIIB secures FDA's Breakthrough Therapy status for litifilimab in cutaneous lupus, backed by phase II results, while advancing phase III and broader lupus studies.
REGNPositive Net Change BIIBNegative Net Change ALKSPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Amgen Set to Report Q4 Earnings: What Investors Should Know
by Zacks Equity Research
AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the quarter.
REGNPositive Net Change AMGNPositive Net Change MRNANegative Net Change
biotechs
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
by Kanishka Das
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
BMRNPositive Net Change RIGLPositive Net Change FOLDNo Net Change
biotechs
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold
by Zacks Equity Research
Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.
REGNPositive Net Change ALKSPositive Net Change NTLANegative Net Change CSTLPositive Net Change
biotechs
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?
by Zacks Equity Research
REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive pressure.
REGNPositive Net Change NVSPositive Net Change VCYTPositive Net Change AMRXPositive Net Change
biotechnology biotechs medical pharmaceuticals